International Journal of Clinical Case Reports, 2025, Vol.15, No.4, 159-170 http://medscipublisher.com/index.php/ijccr 166 associations and trends that are difficult to detect in normal analysis, helping to achieve more proactive and personalized care (Wilfling et al., 2020). Despite the potential, the application of artificial intelligence and big data in comprehensive medication is still rare, and few studies can prove their effective application in practice. Future research should prioritize interdisciplinary collaboration to develop, validate these technologies and apply them in clinical practice, ensuring that healthcare workers can provide effective treatment and management for elderly patients with multiple diseases (Molokhia and Majeed, 2017; Wilfling et al., 2020). 7.3 Establish management standards and social support systems for elderly-friendly medication use Establishing medication norms suitable for the elderly population is of great significance in meeting their special need for multi-drug sharing. This includes establishing guidelines to explain the physical changes due to aging, the coexistence of multiple diseases, the risks of drug interactions, and promoting regular drug checks and reduced prescriptions (Mehta et al., 2021). International trends indicate that home pharmacy services, drug adjustment and tracking of drug-related issues are becoming the main directions of future research and practice (Wu et al., 2025). In addition, strengthening the social support system-such as involving caregivers, pharmacists and community resources-can improve the compliance and safety of medication among the elderly at home or in care institutions. Research should continue to explore effective models that combine social support and clinical care, especially in developing countries where such systems are not yet well developed (Wu et al., 2025). 8 Concluding Remarks The simultaneous use of multiple medications by the elderly is a complex and multi-faceted issue, closely related to various diseases, and may also lead to a series of adverse consequences, such as an increased possibility of hospitalization, inappropriate prescriptions, and death. However, the data shows that the relevant definitions and measurement methods are not uniform, which makes it troublesome to judge the true risks and benefits. To fully understand its impact and guide effective intervention methods, a more systematic and clinically closely related approach to multiple medication operations is needed. To effectively handle the issue of multi-drug sharing, multiple methods need to be employed simultaneously, including checking individual medication use, formulating drug reduction plans, and adopting clear standards (such as STOPP/START) to identify inappropriate prescriptions. Teamwork, especially the coordination between pharmacists and grassroots medical staff, has certain effects in reducing the number of medications patients take and improving the level of prescription, although the impact on the treatment outcome is not yet obvious. Arranging treatment methods based on the core needs and actual situation of the patient is very crucial for improving treatment and reducing harm. Joint efforts in policy, technology and research are crucial to ensuring the medication safety of elderly people suffering from multiple diseases. National guidelines should standardize definitions and best practices, and investing in health information technologies (such as electronic health records and clinical decision support systems) can enhance drug management and reduce errors. Ongoing research should focus on improving risk assessment tools, evaluating the actual effects of intervention measures, and filling evidence gaps, especially for the elderly who are the oldest, the weakest, and in different care Settings. Acknowledgments The author extends sincere thanks to two anonymous peer reviewers for their feedback on the manuscript. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Alkhamsan A., Khamsan A., Zabarah M., Alyami A., Qutayshan A., Aldhuwayin M., Aljarah S., Sulaiman H., Almurdif F., and Alghubari H., 2024, Pharmacist-led interventions for reducing polypharmacy and improving patient outcomes: a systematic review, Journal of Ecohumanism, 3(8): 860-869.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==